The lancet oncology
-
The lancet oncology · Sep 2022
Multicenter Study Retracted PublicationAtezolizumab, vemurafenib, and cobimetinib in patients with melanoma with CNS metastases (TRICOTEL): a multicentre, open-label, single-arm, phase 2 study.
Targeted therapy and immunotherapy have shown intracranial activity in melanoma with CNS metastases, but there remains an unmet need, particularly for patients with symptomatic CNS metastases. We aimed to evaluate atezolizumab in combination with cobimetinib or vemurafenib plus cobimetinib in patients with melanoma with CNS metastases. ⋯ F Hoffmann-La Roche.
-
The lancet oncology · Mar 2022
Retraction Of PublicationRetraction and republication-Stereotactic body radiotherapy plus pembrolizumab and trametinib versus stereotactic body radiotherapy plus gemcitabine for locally recurrent pancreatic cancer after surgical resection: an open-label, randomised, controlled, phase 2 trial.
-
The lancet oncology · Aug 2021
Randomized Controlled Trial Retracted PublicationStereotactic body radiotherapy plus pembrolizumab and trametinib versus stereotactic body radiotherapy plus gemcitabine for locally recurrent pancreatic cancer after surgical resection: an open-label, randomised, controlled, phase 2 trial.
There is paucity of investigations into immunotherapy or targeted therapy for postoperative locally recurrent pancreatic cancer. We aimed to assess the efficacy of stereotactic body radiotherapy (SBRT) plus pembrolizumab and trametinib in these patients. ⋯ For the Chinese translation of the abstract see Supplementary Materials section.
-
The lancet oncology · Jul 2012
Retraction Of PublicationWithdrawn: Cancer detection and primary care...revisited.